Results 121 to 130 of about 1,701 (184)

Virological outcomes, resistance profile and viral evolution of lenacapavir-based regimens in heavily treatment-experienced people: data from the PRESTIGIO Registry. [PDF]

J Antimicrob Chemother
Santoro MM, Spalletta D, Spagnuolo V, Paletti C, Marchegiani G, Bellocchi MC, Lolatto R, Carioti L, Cervo A, Di Biagio A, Fiscon M, Focà E, Gagliardini R, Rusconi S, Zazzi M, Castagna A, Saladini F, Ceccherini-Silberstein F, PRESTIGIO Registry , the.   +19 more
europepmc   +1 more source

Severe lenacapavir injection site nodule

AIDS
Landovitz, Raphael J., Nguyen, Linda
openaire   +1 more source

Brief Report: To Err Is Human, to Persist Is Diabolical: Are We Repeating the Same Cost and Insurance Coverage Mistakes Again With Injectable PrEP? [PDF]

J Acquir Immune Defic Syndr
D'Angelo AB, Patel VV, Carrico AW, Grov C.   +3 more
europepmc   +1 more source

CA Inhibitor 1 Treatment Does Not Affect Estrous Cyclicity in Mice. [PDF]

J Neuroimmune Pharmacol
Giacometti LL, Dalere DM, Lwamba B, Goldberg SL, Feliciano K, Barker JM.   +5 more
europepmc   +1 more source

Challenges facing long-acting PrEP implementation in large populations. [PDF]

Emerg Microbes Infect
Sun C, Liao Y.
europepmc   +1 more source

Long-Acting Antiretroviral Therapy for HIV via Drop-in Community-Based Care.

JAMA Netw Open
Mehtani NJ, Matzat SJ, O'Connor KB, Cordoba L, Strieff S, Strough A, Philbin MM, Johnson MO, Gandhi M, Zevin B.   +9 more
europepmc   +1 more source

Beyond Efficacy: The Access, Delivery Systems, Acceptability, Persistence, and Transition Management "ADAPT" Framework for Long-Acting Injectable PrEP in Sub-Saharan Africa. [PDF]

HIV AIDS (Auckl)
Ikoona EN, Namulemo L, Kaluya R, Ikoona R, Sahr F.   +4 more
europepmc   +1 more source

Author Correction: Potential impact and cost-effectiveness of long-acting injectable lenacapavir plus cabotegravir as HIV treatment in Africa. [PDF]

Nat Commun
Phillips A, Smith J, Bansi-Matharu L, Sikwese K, Kityo C, Flexner C, Vitoria M, Ford N, Doherty M, Panos Z, Ripin D, Hickey M, Havlir D, Gandhi M, Reid M, Revill P.   +15 more
europepmc   +1 more source

HIV capsid inhibitors: Mechanisms, resistance, and therapeutic advances. [PDF]

PLoS Pathog
Mahdi M, Lakatos B, Mótyán JA, Hoffka G, Tőzsér J.   +4 more
europepmc   +1 more source

Effectiveness and Safety of Lenacapavir-Containing Regimens in Highly Experienced HIV-Infected Patients With Multidrug Resistance: Real-world Results From the French Compassionate Use Program ^a. [PDF]

Open Forum Infect Dis
Delaugerre C, Mafi S, Zenuni A, Peytavin G, Amat K, Seang S, Duvivier C, Chirio D, Viard JP, Hocqueloux L, Estrabaud E, Ghosn J, Landman R, Assoumou L, Charpentier C, Lacombe K.   +15 more
europepmc   +1 more source